Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Century Therapeutics
Deal Size : $45.0 million
Deal Type : Acquisition
Century Therapeutics Strengthens Position in Autoimmune with Pipeline Expansion
Details : Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $45.0 million
November 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Century Therapeutics
Deal Size : $45.0 million
Deal Type : Acquisition
Clade Therapeutics Announces the Acquisition of Gadeta B.V.
Details : The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 10, 2023
Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy
Details : Proceeds from this financing will support the development of the Company’s proprietary platform, which enables the immune cloaking of induced pluripotent stem cells (iPSCs) and the differentiation of cloaked stem cells into therapeutic cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 11, 2021
Reset All
